Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$146.34

-4.56 (-3.02%)

, PFE

Pfizer

$43.30

-0.6 (-1.37%)

06:21
07/09/19
07/09
06:21
07/09/19
06:21

Sarepta price target raised to $220 from $165 at Morgan Stanley

Morgan Stanley analyst Matthew Harrison raised his price target for Sarepta Therapeutics (SRPT) to $220 from $165 while keeping an Overweight rating on the shares. The stock closed Monday down $4.52 to $146.28. The company's Duchenne muscular dystrophy gene therapy is positioned to be the first to market, taking a majority share of the ~$20B prevalent population in the U.S. and expanding internationally with a "significant" lead, Harrison tells investors in a research note. He believes Sarepta has higher efficacy than top-line Pfizer (PFE) data suggest. Sarepta's dystrophin expression is likely three-times greater, fiber intensity 15%, and positive fibers 12.5%, contends the analyst. Harrison believes Sarepta has a "broad therapeutic window" and should now take majority market share.

SRPT

Sarepta

$146.34

-4.56 (-3.02%)

PFE

Pfizer

$43.30

-0.6 (-1.37%)

  • 30

    Jul

  • 19

    Aug

  • 28

    Aug

  • 16

    Sep

SRPT Sarepta
$146.34

-4.56 (-3.02%)

07/01/19
RBCM
07/01/19
NO CHANGE
Target $220
RBCM
Outperform
Sarepta price target raised to $220 from $188 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target for Sarepta to $220 from $180 and maintained an Outperform rating, telling investors in a research note that he sees Sarepta as the "clear leader" in the Duchenne Muscular Dystrophy space. The analyst says he looks for initiation of the company's confirmatory study with commercial supply as the next catalyst for this program and expect continued share upside as investors should begin to better appreciate its other gene therapy assets in development. While manufacturing and ability to show functional benefits in a more inclusive study remain risks, Abrahams says he now sees a reasonable likelihood Sarepta can generate $4B per year with microdystrophin.
06/28/19
PIPR
06/28/19
NO CHANGE
Target $208
PIPR
Overweight
'Almost impossible' for Pfizer to compete with Sarepta, says Piper Jaffray
Sarepta Therapeutics (SRPT) went from the front-runner to "basically a standalone" in the Duchenne muscular dystrophy gene therapy race after this morning's data from Pfizer (PFE) showed "serious safety signals" that led to hospitalization in two of six patients dosed, Piper Jaffray analyst Danielle Brill tells investors in a research note. And while Pfizer believes complement activation was driven by a high presence of neutralizing antibodies, the serious adverse event was also observed with Solid Biosciences' (SLDB) gene therapy, which employs the same vector as Pfizer, adds the analyst. As a result, Brill thinks complement activation may be AAV9 related, especially since no such signal has been seen with Sarepta's AAVrh74 vector. In addition, Pfizer has no edge over Sarepta on efficacy either, says the analyst. She thinks it will be "almost impossible" for Pfizer to compete moving forward and reiterates an Overweight rating on Sarepta with a $208 price target. The stock in afternoon trading is up 16%, or $20.61, to $150.37.
06/28/19
WBLR
06/28/19
NO CHANGE
WBLR
Outperform
Sarepta has clear lead in DMD after Pfizer disappoints, says William Blair
William Blair analyst Tim Lugo calls Sarepta Therapeutics (SRPT) the "clear leader" in Duchenne muscular dystrophy without a close number two after this morning's results from Pfizer (PFE) disappointed. Shares of Sarepta are up 15%, or $20.04, to $149.80 in midday trading.
06/28/19
JPMS
06/28/19
NO CHANGE
JPMS
Overweight
Sarepta 'still in pole position' in DMD after Pfizer data, says JPMorgan
JPMorgan analyst Anupam Rama said that Sarepta (SRPT) is "still in the pole position" in Duchenne muscular dystrophy, or DMD, after Pfizer (PFE) presented preliminary data from its own ongoing Phase 1b study of DMD gene therapy PF-06939926. Rama has an Overweight rating on Sarepta shares.
PFE Pfizer
$43.30

-0.6 (-1.37%)

07/08/19
PIPR
07/08/19
NO CHANGE
PIPR
Overweight
BioMarin's Valrox maintains competitive advantage, says Piper Jaffray
After BioMarin (BMRN) announced that the company will submit regulatory filings for Valrox to both the FDA and EMA in Q4, and after the company and competitive partners Sangamo (SGMO) and Pfizer (PFE) both presented updates at this weekend's International Society on Thrombosis and Hemostasis meeting, Piper Jaffray analyst Christopher Raymond said that he still believes the company's roughly 2-year head start puts Valrox at a competitive advantage. Following the confirmation on timing for accelerated filing, Raymond said he would continue to be a buyer of BioMarin shares and he keeps an Overweight rating on the stock.
07/08/19
CANT
07/08/19
DOWNGRADE
Target $48
CANT
Neutral
Array BioPharma downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Varun Kumar downgraded Array BioPharma (ARRY) to Neutral from Overweight while raising his price target for the shares to $48 from $34. The analyst cites the pending takeover by Pfizer (PFE) for the downgrade.

TODAY'S FREE FLY STORIES

TRQ

Turquoise Hill

$1.07

-0.02 (-1.83%)

18:32
07/15/19
07/15
18:32
07/15/19
18:32
Hot Stocks
Turquoise Hill reports Q2 copper output 39.2KT, down 0.6% from last year »

Reports Q2 Gold output…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$61.50

0.77 (1.27%)

18:29
07/15/19
07/15
18:29
07/15/19
18:29
Hot Stocks
Rio Tinto cuts FY19 Pilbara ore shipments view to 320M-330M tons »

Prior view was 333M-343M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

RIO

Rio Tinto

$61.50

0.77 (1.27%)

18:28
07/15/19
07/15
18:28
07/15/19
18:28
Hot Stocks
Rio Tinto report Q2 Pilbara iron ore output 79.7M tons, down 7% from last year »

Reports Q2 Pilbara iron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

VMW

VMware

$172.22

2.48 (1.46%)

18:24
07/15/19
07/15
18:24
07/15/19
18:24
Hot Stocks
VMware: We have momentum across the board »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

CGIX

Cancer Genetics

$0.17

-0.0059 (-3.35%)

, IDXG

Interpace Diagnostics

$0.70

-0.0071 (-1.01%)

18:21
07/15/19
07/15
18:21
07/15/19
18:21
Conference/Events
Interpace Diagnostics to hold a conference call »

Conference call to…

CGIX

Cancer Genetics

$0.17

-0.0059 (-3.35%)

IDXG

Interpace Diagnostics

$0.70

-0.0071 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:55
07/15/19
07/15
17:55
07/15/19
17:55
Conference/Events
Stephens business services analyst to hold a group dinner »

Group Dinner Meeting to…

EYEN

Eyenovia

$2.89

0.04 (1.40%)

17:51
07/15/19
07/15
17:51
07/15/19
17:51
Hot Stocks
Eyenovia CEO buys 233.8K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ET

Energy Transfer LP

$14.91

0.09 (0.61%)

17:38
07/15/19
07/15
17:38
07/15/19
17:38
Periodicals
Energy Transfer considering sale of 33% Rover pipeline stake, Bloomberg says »

Energy Transfer (ET) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INNT

Innovate Biopharmaceuticals

$1.12

0.02 (1.82%)

17:37
07/15/19
07/15
17:37
07/15/19
17:37
Hot Stocks
Innovate Biopharmaceuticals gives corporate update, undertakes CEO search effort »

Innovate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAMR

Lamar Advertising

$80.70

-0.31 (-0.38%)

17:36
07/15/19
07/15
17:36
07/15/19
17:36
Hot Stocks
Lamar Advertising to acquire Ashby Street Outdoor Holdings »

Ashby Street Outdoor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

LMT

Lockheed Martin

$367.65

-1.81 (-0.49%)

17:24
07/15/19
07/15
17:24
07/15/19
17:24
Hot Stocks
Lockheed Martin awarded $492.11M Army contract for M142 launchers »

Lockheed Martin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

EGHT

8x8, Inc.

$25.62

-0.24 (-0.93%)

, FIVN

Five9

$48.00

-5.53 (-10.33%)

17:15
07/15/19
07/15
17:15
07/15/19
17:15
Conference/Events
Stephens communications analysts to hold an analyst/industry conference call »

Communications Analysts,…

EGHT

8x8, Inc.

$25.62

-0.24 (-0.93%)

FIVN

Five9

$48.00

-5.53 (-10.33%)

LOGM

LogMeln

$76.57

0.41 (0.54%)

RNG

RingCentral

$123.31

0.34 (0.28%)

WORK

Slack Technologies

$34.78

1.04 (3.08%)

TWLO

Twilio

$145.36

3.185 (2.24%)

VG

Vonage

$12.79

-0.2 (-1.54%)

ZM

Zoom Video

$99.76

6.465 (6.93%)

GOOG

Alphabet

$1,150.39

5.84 (0.51%)

MSFT

Microsoft

$138.94

0.08 (0.06%)

AMZN

Amazon.com

$2,021.00

10.38 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 27

    Oct

  • 13

    Nov

WTI

W&T Offshore

$4.83

0.13 (2.77%)

17:08
07/15/19
07/15
17:08
07/15/19
17:08
Hot Stocks
W&T Offshore CEO buys 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRT

StarTek

$7.10

0.04 (0.57%)

17:08
07/15/19
07/15
17:08
07/15/19
17:08
Syndicate
Breaking Syndicate news story on StarTek »

StarTek files $100M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

VTVT

vTv Therapeutics

$1.37

(0.00%)

17:08
07/15/19
07/15
17:08
07/15/19
17:08
Hot Stocks
vTv Therapeutics jumps 20% after saying it will make presentation at AAIC »

vTv Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBHT

J.B. Hunt

$92.50

-0.45 (-0.48%)

16:53
07/15/19
07/15
16:53
07/15/19
16:53
Hot Stocks
Breaking Hot Stocks news story on J.B. Hunt »

J.B. Hunt up over 6% at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 26

    Aug

  • 13

    Nov

ARW

Arrow Electronics

$68.82

-0.15 (-0.22%)

16:52
07/15/19
07/15
16:52
07/15/19
16:52
Hot Stocks
Breaking Hot Stocks news story on Arrow Electronics »

Arrow Electronics down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBNK

United Financial

$14.02

-0.1 (-0.71%)

16:45
07/15/19
07/15
16:45
07/15/19
16:45
Hot Stocks
Breaking Hot Stocks news story on United Financial »

United Financial trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

TRWH

Twin River Worldwide

$28.90

-0.08 (-0.28%)

16:44
07/15/19
07/15
16:44
07/15/19
16:44
Hot Stocks
Standard General to tender 13M shares from Twin River Worldwide »

Twin River Worldwide…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HQY

HealthEquity

$70.29

-1.38 (-1.93%)

16:44
07/15/19
07/15
16:44
07/15/19
16:44
Hot Stocks
HealthEquity director Robert Selander buys 610K in company shares »

HealthEquity director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSS

TSYS

$133.45

1.26 (0.95%)

, GPN

Global Payments

$165.94

1.69 (1.03%)

16:39
07/15/19
07/15
16:39
07/15/19
16:39
Hot Stocks
Global Payments establishes new credit agreement to support merger with TSYS »

Global Payment (GPN)…

TSS

TSYS

$133.45

1.26 (0.95%)

GPN

Global Payments

$165.94

1.69 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 13

    Nov

ECOR

electroCore

$1.61

0.01 (0.63%)

16:34
07/15/19
07/15
16:34
07/15/19
16:34
Syndicate
electroCore files registration statement on Form S-3 »

electroCore announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFMS

Conformis

$3.40

-0.265 (-7.23%)

16:31
07/15/19
07/15
16:31
07/15/19
16:31
Hot Stocks
Conformis announces alliance with Regent Surgical Health »

Conformis announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

VIAB

Viacom

$31.72

0.02 (0.06%)

, VIA

Viacom

$36.15

-0.15 (-0.41%)

16:30
07/15/19
07/15
16:30
07/15/19
16:30
Periodicals
CBS and Viacom set August deadline for merger talks, CNBC reports »

According to CNBC's…

VIAB

Viacom

$31.72

0.02 (0.06%)

VIA

Viacom

$36.15

-0.15 (-0.41%)

CBS

CBS

$53.37

0.18 (0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

16:30
07/15/19
07/15
16:30
07/15/19
16:30
Options
Preliminary option volume of 15.2M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.